Skip to content
Dr. Grey AI

Condition

Neuroendocrine Tumors

Neuroendocrine tumors are growths that arise from hormone-producing cells, most often in the gut, pancreas, or lungs, and many grow slowly. Octreotide, lanreotide, and lutetium-177 dotatate have the strongest evidence, and large trials found tumors took longer to progress, with the risk of progression or death falling by 79% in one lutetium study. Much of this work involved advanced midgut tumors, so results may not apply to every type.

Sources: PMID 34793718; PMID 19704057

Supplements studied
0
Medicines and peptides
3
Graded outcomes
12
No supplement studies yetWe haven’t found supplement studies for Neuroendocrine Tumors. The medicines and peptides studied for it are listed below.

Prescription medicines and peptides studied, for context

These are not supplements. Most need a prescription, and some are research compounds with no approved use.

3 medicines and peptides

Lanreotide (Somatuline)

Lanreotide (Somatuline): outcomes studied for Neuroendocrine Tumors
GradeOutcomeEffectSizeStudiesPeopleStudies list
Tumor Stabilization (NETs)

Stable disease rates of 15-89% in clinical trials. Phase II studies show significant antitumor effects with disease control in majority of patients.

Improves (the measure goes up)Large effect25 studies

Studies that measured tumor stabilization (nets)

and 22 more on the Lanreotide (Somatuline) page

Progression-Free Survival (NETs)

CLARINET trial: 53% reduction in disease progression risk (HR 0.47, P<0.001). 65.1% vs 33.0% PFS at 24 months. Median PFS not reached vs 18 months placebo.

Improves (the measure goes up)Large effect24 studies

Studies that measured progression-free survival (nets)

and 21 more on the Lanreotide (Somatuline) page

Carcinoid Syndrome Symptoms

FDA-approved for symptomatic control of flushing and diarrhea associated with carcinoid syndrome. Significant QOL improvement in symptomatic patients.

Improves (the measure goes down)Large effect22 studies

Studies that measured carcinoid syndrome symptoms

and 19 more on the Lanreotide (Somatuline) page

VIPoma Symptoms

Effective for controlling watery diarrhea and electrolyte disturbances in VIP-secreting tumors.

Improves (the measure goes down)Large effect22 studies

Studies that measured vipoma symptoms

and 19 more on the Lanreotide (Somatuline) page

Lutetium-177 Dotatate (Lutathera)

Lutetium-177 Dotatate (Lutathera): outcomes studied for Neuroendocrine Tumors
GradeOutcomeEffectSizeStudiesPeopleStudies list
Progression-Free Survival

NETTER-1: 65.2% PFS rate at month 20 vs 10.8% control. 79% reduction in progression/death risk. Median PFS not reached vs ~8 months control. Doubled median PFS from 9 to 23 months in GEP-NETs.

Improves (the measure goes up)Large effect19 studies

Studies that measured progression-free survival

and 16 more on the Lutetium-177 Dotatate (Lutathera) page

Overall Survival

Final NETTER-1: Median OS 48.0 months vs 36.3 months control (11.7 month benefit). HR 0.84. Clinically meaningful survival advantage despite P=0.30 due to crossover.

Improves (the measure goes up)Large effect18 studies

Studies that measured overall survival

and 15 more on the Lutetium-177 Dotatate (Lutathera) page

Objective Response Rate

NETTER-1: Significantly higher ORR with 177Lu-DOTATATE vs control. 16% ORR including complete responses in ERASMUS study subset. Tumor shrinkage correlates with improved outcomes.

Improves (the measure goes up)Large effect17 studies

Studies that measured objective response rate

and 14 more on the Lutetium-177 Dotatate (Lutathera) page

Quality of Life

Time to QoL deterioration: 28.8 months vs 6.1 months (global health). Physical functioning: 25.2 months vs 11.5 months. Clinically significant improvements maintained long-term.

Improves (the measure goes up)Large effect17 studies

Studies that measured quality of life

and 14 more on the Lutetium-177 Dotatate (Lutathera) page

Octreotide (Sandostatin)

  • Tumor Progression (NETs): improves
  • Carcinoid Syndrome Symptoms: improves
  • VIPoma Diarrhea: improves
Octreotide (Sandostatin): outcomes studied for Neuroendocrine Tumors
GradeOutcomeEffectSizeStudiesPeopleStudies list
Tumor Progression (NETs)

PROMID trial showed median time to tumor progression of 14.3 months vs 6 months placebo (HR 0.34, P<0.001) in metastatic midgut NETs.

Improves (the measure goes down)Large effect18 studies

Studies that measured tumor progression (nets)

and 15 more on the Octreotide (Sandostatin) page

Carcinoid Syndrome Symptoms

Over 70% of patients achieve significant improvement or resolution of diarrhea and flushing with octreotide LAR treatment.

Improves (the measure goes down)Large effect18 studies

Studies that measured carcinoid syndrome symptoms

and 15 more on the Octreotide (Sandostatin) page

VIPoma Diarrhea

FDA-approved for watery diarrhea associated with VIP-secreting tumors, with significant symptom improvement.

Improves (the measure goes down)Large effect18 studies

Studies that measured vipoma diarrhea

and 15 more on the Octreotide (Sandostatin) page

Survival (NETs)

Retrospective data suggest improved 5-year survival (67% vs 18% historical controls) in advanced GEP-NETs treated with octreotide.

Improves (the measure goes up)Moderate effect18 studies

Studies that measured survival (nets)

and 15 more on the Octreotide (Sandostatin) page

Key findings

  • Tumor Stabilization (NETs)Lanreotide (Somatuline)Improves (the measure goes up)
  • Progression-Free Survival (NETs)Lanreotide (Somatuline)Improves (the measure goes up)
  • Carcinoid Syndrome SymptomsLanreotide (Somatuline)Improves (the measure goes down)

Safety notes in the studies

  • CLARINET trial: 53% reduction in disease progression risk (HR 0.47, P<0.001).
  • 79% reduction in progression/death risk.

Studies cited

100 studies from PubMed

  1. Lanreotide protects against LPS-induced inflammation in endothelial cells and mouse lungs.Tissue barriers, 2025 · PMID 40241488
  2. Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.Scientific reports, 2025 · PMID 40437077
  3. Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.Endocrine, 2025 · PMID 40468101
  4. Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 TrialEur J Nucl Med Mol Imaging, 2025 · PMID 39947918
  5. Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 TrialOncologist, 2025 · PMID 40272146
  6. Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors.Journal of clinical medicine, 2025 · PMID 40217834
  7. Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania), 2025 · PMID 40870386
  8. Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.Current treatment options in oncology, 2025 · PMID 39843688
  9. Variations in Octreotide Dosing in Published Reports of Sulfonylurea Toxicity: A Systematic Review, 1988-Present.Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2025 · PMID 39821850
  10. The use of octreotide in pediatric patients: Practical applications for gastrointestinal disorders and beyond: A narrative review.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2025 · PMID 40629899
  11. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.The oncologist, 2024 · PMID 38206830
  12. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.Expert opinion on drug safety, 2024 · PMID 38847075
  13. 177Lu-DOTATATE in Peptide Receptor Radionuclide Therapy: A Decade of Experience and EvolutionJ Nucl Med, 2024 · PMID 38117118
  14. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.Targeted oncology, 2024 · PMID 38108953
  15. Comparison of the tolerability of (161)Tb- and (177)Lu-labeled somatostatin analogues in the preclinical setting.European journal of nuclear medicine and molecular imaging, 2024 · PMID 39046521
  16. Time toxicity of lutetium 177 in gastroenteropancreatic neuroendocrine tumours.Endocrine oncology (Bristol, England), 2024 · PMID 39649116
  17. 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2024 · PMID 39026463
  18. Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment.Frontiers in endocrinology, 2024 · PMID 39735644
  19. Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1J Clin Endocrinol Metab, 2024 · PMID 39378125
  20. Octreotide efficacy and safety in children with hyperinsulinism: evidence from two Chinese centers.European journal of pediatrics, 2024 · PMID 39565408
  21. Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.Annals of surgery, 2024 · PMID 38662619
  22. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.Journal of hematology & oncology, 2023 · PMID 38098114
  23. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.Neuroendocrinology, 2023 · PMID 36044870
  24. Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.Pharmaceutics, 2023 · PMID 37111725
  25. Safety and Efficacy of 177 Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease.Clinical nuclear medicine, 2023 · PMID 37167406
  26. Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium-177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience.Cancers, 2023 · PMID 37760475
  27. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.Radiology. Imaging cancer, 2023 · PMID 37477566
  28. The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism.The Journal of clinical endocrinology and metabolism, 2022 · PMID 35587448
  29. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 ((177)Lu)-DOTATATE.Cancer biotherapy & radiopharmaceuticals, 2022 · PMID 34134512
  30. Lutetium-177 DOTATATE: A Practical Review.Practical radiation oncology, 2022 · PMID 35717045
  31. Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review.Pharmaceutics, 2022 · PMID 35890290
  32. Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With AcromegalyPituitary, 2022 · PMID 35452815
  33. IVIVC of Octreotide in PLGA-Glucose Microsphere Formulation, Sandostatin® LAR.AAPS PharmSciTech, 2022 · PMID 36123513
  34. Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly.Expert review of clinical pharmacology, 2021 · PMID 34664531
  35. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialLancet Oncol, 2021 · PMID 34793718
  36. NETTER-2 trial protocol: a prospective, international, open-label, randomized phase 3 study of 177Lu-DOTATATE compared with octreotide LAR in somatostatin receptor-positive, grade 2-3, midgut neuroendocrine tumorsBMC Cancer, 2021 · PMID 33947893
  37. Initial experience and lessons learned with implementing Lutetium-177-dotatate radiopharmaceutical therapy in a radiation oncology-based program.Brachytherapy, 2021 · PMID 32819853
  38. A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy.Endocrine-related cancer, 2021 · PMID 33608484
  39. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021 · PMID 33771903
  40. The use of high dose octreotide in management of neonatal chylothorax: Review.Journal of neonatal-perinatal medicine, 2021 · PMID 33843702
  41. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).BMC endocrine disorders, 2020 · PMID 32366244
  42. Cost-effectiveness of lutetium ((177)Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden.World journal of clinical cases, 2020 · PMID 33195647
  43. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).Trials, 2020 · PMID 32024533
  44. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.The Lancet. Oncology, 2020 · PMID 32112737
  45. Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.Lung cancer (Amsterdam, Netherlands), 2019 · PMID 31319970
  46. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.Gastroenterology, 2019 · PMID 31022403
  47. Further Evidence That Lanreotide Reduces Liver Growth in Patients With Polycystic Liver Disease, But Not the End of the Story.Gastroenterology, 2019 · PMID 31260661
  48. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.Investigational new drugs, 2019 · PMID 30536151
  49. The safety of lanreotide for neuroendocrine tumor.Expert opinion on drug safety, 2019 · PMID 30582380
  50. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide TherapyPharmaceuticals (Basel), 2019 · PMID 31362406
  51. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumorsExpert Rev Gastroenterol Hepatol, 2019 · PMID 31652074
  52. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.Cureus, 2019 · PMID 30972265
  53. Therapy With (177)Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors.AJR. American journal of roentgenology, 2019 · PMID 31039017
  54. Protection of Kidney Function with Human Antioxidation Protein α(1)-Microglobulin in a Mouse (177)Lu-DOTATATE Radiation Therapy Model.Antioxidants & redox signaling, 2019 · PMID 29943622
  55. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter studyCancer Chemother Pharmacol, 2019 · PMID 30535537
  56. Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID TrialNeuroendocrinology, 2019 · PMID 30852564
  57. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.Tumori, 2019 · PMID 29714658
  58. Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors.Nuclear medicine communications, 2019 · PMID 31365494
  59. ANNIVERSARY REVIEW: Octreotide, 40 years later.European journal of endocrinology, 2019 · PMID 31398712
  60. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trialsPituitary, 2018 · PMID 29357081
  61. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018 · PMID 29547049
  62. Cost-effectiveness of acromegaly treatments: a systematic review.Pituitary, 2018 · PMID 30159696
  63. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 TrialJ Clin Oncol, 2018 · PMID 29878866
  64. Gastroenteropancreatic Neuroendocrine Tumors.CA: a cancer journal for clinicians, 2018 · PMID 30295930
  65. The effect of kidney volume estimation on dosimetry in lutetium-177 DOTATATE therapy.Nuclear medicine communications, 2018 · PMID 29528911
  66. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.Health technology assessment (Winchester, England), 2018 · PMID 30209002
  67. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.The oncologist, 2017 · PMID 28220021
  68. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsN Engl J Med, 2017 · PMID 28076709
  69. Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research, 2017 · PMID 28428192
  70. Medical Therapy of Gastrointestinal Neuroendocrine Tumors.Visceral medicine, 2017 · PMID 29177164
  71. Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET.Nuclear medicine communications, 2017 · PMID 28471845
  72. Octreotide use and safety in infants with hyperinsulinism.Pharmacoepidemiology and drug safety, 2017 · PMID 27910218
  73. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2017 · PMID 28459498
  74. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.Expert opinion on pharmacotherapy, 2016 · PMID 26635177
  75. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.Current oncology reports, 2016 · PMID 26743514
  76. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.Clinical advances in hematology & oncology : H&O, 2016 · PMID 27168103
  77. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.Endocrine-related cancer, 2016 · PMID 26743120
  78. Octreotide - A Review of its Use in Treating Neuroendocrine TumoursEur Oncol Haematol, 2016 · PMID 29872467
  79. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors.Journal of drug targeting, 2015 · PMID 25366085
  80. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015 · PMID 26073493
  81. Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases.Current topics in medicinal chemistry, 2015 · PMID 26126910
  82. Pasireotide in Acromegaly: A Review.Drugs, 2015 · PMID 26017304
  83. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trialJ Clin Endocrinol Metab, 2015 · PMID 25664604
  84. Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.British journal of clinical pharmacology, 2015 · PMID 26076191
  85. Lanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med, 2014 · PMID 25014687
  86. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trialJ Clin Endocrinol Metab, 2014 · PMID 24423301
  87. Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Drugs, 2014 · PMID 25193626
  88. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.The lancet. Diabetes & endocrinology, 2014 · PMID 25260838
  89. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysisJ Clin Endocrinol Metab, 2014 · PMID 24606084
  90. From somatostatin to octreotide LAR: evolution of a somatostatin analogueGastrointest Endosc, 2013 · PMID 23715783
  91. Octreotide acetate-steroid combination therapy for malignant gastrointestinal obstruction.Anticancer research, 2013 · PMID 24324097
  92. Octreotide for primary moderate to severe acute pancreatitis: a meta-analysis.Hepato-gastroenterology, 2013 · PMID 24298575
  93. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.Lung cancer (Amsterdam, Netherlands), 2012 · PMID 22018594
  94. Successful treatment of congenital hyperinsulinism with long-acting release octreotide.European journal of endocrinology, 2012 · PMID 22048969
  95. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel).The Journal of clinical endocrinology and metabolism, 2011 · PMID 21697252
  96. Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.Annals of nuclear medicine, 2011 · PMID 21476058
  97. Sustained-release delivery of octreotide from biodegradable polymeric microspheres.AAPS PharmSciTech, 2011 · PMID 21948321
  98. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionPituitary, 2010 · PMID 19639415
  99. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.Pituitary, 2010 · PMID 19189218
  100. Antitumor effects of somatostatin analogs in neuroendocrine tumorsJ Exp Clin Cancer Res, 2010 · PMID 22505462